What is Erste Group Bank’s Forecast for BMY FY2027 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Investment analysts at Erste Group Bank boosted their FY2027 earnings estimates for shares of Bristol Myers Squibb in a research note issued to investors on Thursday, August 27th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings per share of $6.53 for the year, up from their previous forecast of $6.51. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

A number of other brokerages have also recently commented on BMY. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Piper Sandler started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an “overweight” rating on the stock. Guggenheim reaffirmed a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating on the stock. Finally, Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $66.93 on Monday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The company’s fifty day moving average price is $62.01 and its 200-day moving average price is $59.72. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $68.64. The firm has a market capitalization of $136.72 billion, a PE ratio of 14.74, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Institutional Investors Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently made changes to their positions in the company. Northwestern Mutual Investment Management Company LLC increased its holdings in Bristol Myers Squibb by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock valued at $3,509,000 after buying an additional 172 shares in the last quarter. KCM Investment Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after acquiring an additional 174 shares in the last quarter. Sandy Cove Advisors LLC grew its position in shares of Bristol Myers Squibb by 4.7% during the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 176 shares during the period. Investment Research Partners LLC grew its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after acquiring an additional 179 shares during the period. Finally, ESG Planning DBA Harper Investing increased its stake in shares of Bristol Myers Squibb by 1.3% in the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 180 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.